阿米洛里德降低了果糖胺-3-激酶的表达,以恢复利尼布在细胞癌的敏感性
Yuanyuan Bai1, Yiqing You2, Daoxun Chen1
1Department of Urology, Affiliated Sanming First Hospital, Fujian Medical University, Sanming, Fujian 365100, P.R. China.
iScience
|June 13, 2024
概括
阿米洛里德通过向FN3K和VEGFR2.2,增强了对细胞癌 (RCC) 的苏尼替尼的有效性. 这种组合疗法显示出协同作用的抗癌作用,为RCC治疗提供了一种新的策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 细胞癌 (RCC) 是一个重大的健康问题.
- 苏尼蒂尼布是针对RCC的向治疗,但可以产生耐药性.
- 阿米洛里德在增强抗癌药物敏感性的作用正在调查中.
研究的目的:
- 研究阿米洛里德和苏尼蒂尼布在细胞癌 (RCC) 的协同作用.
- 阐明阿米洛里德在RCC中增强逊尼提尼布敏感性的分子机制.
主要方法:
- 在RCC细胞系的体外和体内研究.
- 质谱学 (MS/TMT) 用于蛋白质表达的分析.
- 共同免疫沉 (Co-IP) 和免疫光 (IF) 用于蛋白相互作用分析.
主要成果:
- 苏尼提尼布和阿米洛里德对RCC细胞表现出协同性细胞毒性.
- 纤维肌菌素III型域含有蛋白3 (FN3K) 被苏尼替尼上调和被阿米洛里德下调.
- 通过调节VEGFR2并激活AKT/mTOR通路,FN3K促进了RCC的扩散,入侵,转移,并降低了sunitinib的敏感性.
- 阿米洛里德治疗挽救了FN3K和VEGFR2的积累,并破坏了它们的相互作用.
结论:
- 由VEGFR2中断介导的FN3K枯竭是阿米洛里德与苏尼蒂尼布的协同抗RCC活性的一个关键机制.
- 这种组合疗法为克服RCC中苏尼提尼布耐药性的有希望的策略.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.5K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
512
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
512
01:25Antihypertensive Drugs: Direct Renin Inhibitors
567
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
567
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
968
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
968